Skip to content

R&D at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$336M-1.8%
Natera, Inc. logo
Natera, Inc.NTRA
$210.7M+63.2%
NeoGenomics logo
NeoGenomicsNEO
$9.53M-6.4%
Personalis, Inc. logo
Personalis, Inc.PSNL
$14.54M+15.0%
GeneDx Holdings logo
GeneDx HoldingsWGS
$19.8M+57.5%
TransMedics Group, Inc. logo
TransMedics Group, Inc.TMDX
$24.88M+45.0%

Other financials

Income statement

See full
Revenue$117.7M+39.0%
Operating income$1.2M+109%
Net income$2.8M+127%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$78.5M-12.1%
Total debt$24.5M-19.1%
Total equity$313.5M-17.3%
Total assets$411.1M-16.0%

Cash flow

See full
Operating cash flow$4.3M+116%
CapEx$3.8M+134%
Free cash flow$514.0K+102%

Valuation

See full
Market cap$1.4B+32.2%
Enterprise value$1.35B+34.6%
P/S3.4×+0.3×

Profitability

See full
Gross margin65.5%
Operating margin-3.9%-18.3pp
Net margin-2%-19.9pp
FCF margin-0%0.0pp

Returns & leverage

See full
Return on equity-2.4%-21.9pp
Debt / equity0.1×0.0×
Current ratio3.4×-0.7×

Where this comes from

Reported directly by CareDx in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: CareDx’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about CareDx's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CareDx's R&D?
CareDx (CDNA) reported R&D of $21.42M in Q1 2026.
How has CareDx's R&D changed year-over-year?
CareDx's R&D increased by 15.6% year-over-year, from $18.52M to $21.42M.
What is the long-term trend for CareDx's R&D?
Over 4 years (2021 to 2025), CareDx's R&D has grown at a -1.7% compound annual growth rate (CAGR), from $76.53M to $71.43M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.